Achillion nominates ACH-2928 NS5A clinical applicant in the course of treatment of HCV
Posted in Disease, Infection on July 21st, 2010Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a kingpin in the conception and incident of treatments benefit of the most challenging contagious diseases, today announced the nomination of a kick off b lure clinical prospect in its fourth proprietary program against hepatitis C virus (HCV) infection. The entrant, ACH-2928, is an NS5A inhibitor that in preclinical studies has demonstrated tickety-boo potency against HCV RNA replication, as through Read the rest of this entry »
